92420
document
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status . Cell death after treatment with chemotherapy is exerted by activation of apoptosis , and the p53 protein has been shown to actively participate in this process . This recent focus on TP53 status as a possible determinant of cancer therapy response has raised the question of whether or not mutations in the TP53 gene have an influence on paclitaxel therapy . The TP53 status has been analysed at the DNA level in tumours from 45 ovarian cancer patients randomized to treatment with paclitaxel and cisplatin or cyclophosphamide and cisplatin . Therapy response was obtained for 38 patients with clinically evaluable disease after initial surgery . The positive response rate to the paclitaxel/cisplatin therapy was 85 % vs 61 % for the patients who received the cyclophosphamide/cisplatin regimen . A significant difference in relapse-free survival in favour of paclitaxel/cisplatin chemotherapy was found ( P = 0.001 ) . A total of 33 tumour samples ( 73 % ) had detectable sequence alterations in the TP53 gene . When relapse-free survival was estimated for all patients with TP53 alterations in their tumours , a significant better outcome for the paclitaxel/cisplatin group was found compared with the patient group receiving cyclophosphamide and cisplatin therapy ( P = 0.002 ) . We did not observe an association between TP53 tumour status and prognosis for patients who received paclitaxel/cisplatin combination treatment , indicating that the effect of this therapy is not influenced by this parameter .
92421
Intervention_Control
paclitaxel or cyclophosphamide combination treatment
92422
Intervention_Pharmacological
chemotherapy
92423
Intervention_Pharmacological
paclitaxel
92424
Intervention_Pharmacological
paclitaxel
92425
Intervention_Pharmacological
cyclophosphamide
92426
Intervention_Pharmacological
cisplatin
92427
Intervention_Pharmacological
paclitaxel/cisplatin
92428
Intervention_Pharmacological
cyclophosphamide/cisplatin
92429
Intervention_Pharmacological
paclitaxel/cisplatin chemotherapy
92430
Intervention_Pharmacological
paclitaxel/cisplatin
92431
Intervention_Pharmacological
cyclophosphamide
92432
Intervention_Pharmacological
cisplatin
92433
Intervention_Pharmacological
paclitaxel/cisplatin
92434
Outcome_Other
Therapy effect
92435
Outcome_Physical
TP53 status
92436
Outcome_Physical
TP53 status
92437
Outcome_Other
Therapy response
92438
Outcome_Physical
positive response rate
92439
Outcome_Mortality
relapse-free survival
92440
Outcome_Physical
sequence alterations in the TP53 gene
92441
Outcome_Mortality
relapse-free survival
92442
Outcome_Physical
TP53 alterations
92443
Outcome_Physical
TP53 tumour status
92444
Participant_Condition
epithelial ovarian cancer
92445
Participant_Sample-size
45
92446
Participant_Condition
ovarian cancer
92447
Participant_Sample-size
38